MedTrace Logo

Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease

NCT01241968 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-02-20

No results posted yet for this study

Summary

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones.

The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.

Conditions

  • Refractory Angina Pectoris

Interventions

DEVICE

Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)

Energy Density - 0.09 mJ/mm2

DEVICE

Placebo

Placebo

Sponsors & Collaborators

  • Universität Duisburg-Essen

    collaborator OTHER

  • Medispec

    lead INDUSTRY

Principal Investigators

  • Alexander Lind, MD · Westdeutsches Herzzentrum ,Universität Duisburg/Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-08-31
Completion
2013-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01241968 on ClinicalTrials.gov